Flag of the European Union EU Clinical Trials Register Help

Clinical trials for L-alanine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    31 result(s) found for: L-alanine. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2009-012602-39 Sponsor Protocol Number: 05-NEOV-002 Start Date*: 2010-05-17
    Sponsor Name:Fresenius Kabi Deutschland GmbH
    Full Title: A randomised, double-blind study evaluating the safety, tolerability, protein accretion, amino acid plasma levels and long-term outcome of Neoven compared to Vaminolact(R) in premature very low bir...
    Medical condition: The product is aimed to be used where parenteral nutrition is required. The intended indication is: Supply of essential and non-essential amino acids as part of parenteral nutrition for premature ...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10051284 Parenteral nutrition LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012604-92 Sponsor Protocol Number: 05-NEOV-004 Start Date*: 2010-04-19
    Sponsor Name:Fresenius Kabi Deutschland GmbH
    Full Title: A randomised, double-blind study of the safety and efficacy of Neoven compared to Vaminolact in infants and children requiring long-term parenteral nutrition
    Medical condition: The product is aimed to be used where parenteral nutrition is required. The intended indication is: Supply of essential and non-essential amino acids as part of Parenteral Nutrition for infants an...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10051284 Parenteral nutrition LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000429-20 Sponsor Protocol Number: 05-NEOV-001 Start Date*: 2008-10-17
    Sponsor Name:Fresenius Kabi Deutschland GmbH
    Full Title: A randomised, double-blind study evaluating the safety, tolerability, and amino acid plasma levels of Neoven compared to Vaminolact in infants after surgical interventions.
    Medical condition: The product is aimed to be used where parenteral nutrition is required. The indended indication is: Supply of essential and non-essential amino acids as part of parenteral nutrition for preterm an...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051284 Parenteral nutrition LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012603-26 Sponsor Protocol Number: 05-NEOV-003 Start Date*: 2010-04-08
    Sponsor Name:Fresenius Kabi Deutschland GmbH [...]
    1. Fresenius Kabi Deutschland GmbH
    2. Fresenius Kabi Deutschland GmbH
    Full Title: A randomised, double-blind study evaluating the safety, tolerability and clinical outcome of Neoven compared to Vaminolact in premature ELBW infants
    Medical condition: The product is aimed to be used where parenteral nutrition is required. The intended indication is: Supply of essential and non-essential amino acids as part of Parenteral Nutrition for premature ...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10051284 Parenteral nutrition LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-006153-31 Sponsor Protocol Number: CSC/P01/07/Mu.F Start Date*: 2008-04-23
    Sponsor Name:Baxter R and D Europe SCRL
    Full Title: Safety and efficacy of subcutaneous (SC) administration of Clinimix N9G15E in elderly patients at risk for malnutrition, at a dose of 1 liter infused over 12 hours for 7 to 10 consecutive days. A p...
    Medical condition: The population studied will be the elderly population at risk for malnutrition without any predefined pathology at hospital geriatrician wards.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051284 Parenteral nutrition PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-017064-16 Sponsor Protocol Number: PRODIGE16 Start Date*: 2010-03-01
    Sponsor Name:Fédération Francophone de Cancérologie Digestive
    Full Title: Essai randomisé en double aveugle de phase II/III évaluant la chimioembolisation combinée au sunitinib ou à un placebo chez des patients atteints de carcinome hépatocellulaire (SATURNE)
    Medical condition: Patients présentant un carcinome hépatocellulaire non accessible à une résection chirurgicale ou à une radiofréquence, pouvant bénéficier d'une chimioembolisation trans-artéreille (TACE)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-000280-84 Sponsor Protocol Number: ML28882 Start Date*: 2013-08-15
    Sponsor Name:Finnish melanoma group
    Full Title: COBRA: TOL+ INTERFERON-alpha COMBINED WITH VEMURAFENIB (BRAF-mutation positive patients) OR TOL + INTERFERON- alpha (BRAF-mutation negative patients) FOR PATIENTS WITH ADVANCED MELANOMA AS 1st CHEM...
    Medical condition: Patients with histologically confirmed metastatic melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000164-93 Sponsor Protocol Number: 1000000 Start Date*: 2006-05-10
    Sponsor Name:Department of Anesthesiology University Hospital Center
    Full Title: Effect of Nutritional Support on Liver Integrity during General Anesthesia for Laparoscopic Cholecystectomy. A Pilot Study
    Medical condition: To the best of our knowledge, there is no clinical study on the protective effect of nutritional support on the liver in the perioperative setting using clinical and biological variables. Regarding...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000577-29 Sponsor Protocol Number: S187.3.001 Start Date*: 2007-04-27
    Sponsor Name:Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
    Full Title: A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson’s Subjects Receiving Optimized Treatments with...
    Medical condition: Treatment of levodopa-responsive Parkinson's subjects with severe motor fluctuations.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003571-12 Sponsor Protocol Number: GLU0409 Start Date*: 2006-11-15
    Sponsor Name:Barts and the London NHS Trust
    Full Title: Breath Methionine and Other Indices of Oxidant Stress in the Critical Care Setting. The effect of two doses of Dipeptiven given independently of parenteral nutrition.
    Medical condition: 60 consecutive critically ill patients will be recruited with illnesses such as severe infection, trauma and post-surgery.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-004112-28 Sponsor Protocol Number: URO-EMDA-2022-1 Start Date*: 2023-03-27
    Sponsor Name:Guillem Abad Carratalà
    Full Title: Randomized prospective study of the impact of preoperative instillation of mitomycin-C by electromotive drug administration (EMDA) in patients with non-muscle-infiltrating urothelial carcinoma
    Medical condition: Non muscle invasive bladder tumor
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005009 Bladder cancer stage I, without cancer in situ PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000998-31 Sponsor Protocol Number: APHP220267 Start Date*: 2023-03-10
    Sponsor Name:ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP)
    Full Title: Study of the benefit of lenvatinib treatment in waiting list of liver transplantation after TACE failure in patients with hepatocellular carcinoma (HCC) : Ta-Len-Tra.
    Medical condition: Patients with a non resectable HCC registered on national waiting list for LT with no complete response to TACE as a bridging loco-regional treatment.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002068-15 Sponsor Protocol Number: EMN20 Start Date*: 2019-05-15
    Sponsor Name:FO.NE.SA.Onlus
    Full Title: CARFILZOMIB - LENALIDOMIDE - DEXAMETHASONE (KRd) versus LENALIDOMIDE - DEXAMETHASONE (Rd) IN NEWLY DIAGNOSED MYELOMA PATIENTS NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION: A RANDOMIZED PHA...
    Medical condition: PATIENTS WITH NEW DIAGNOSIS MM WITH AGE ≥ 65 YEARS OR NOT ELIGIBLE TO ASCT
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000782-53 Sponsor Protocol Number: UNITO-MM-01/FORTE Start Date*: 2015-01-12
    Sponsor Name:Università degli Studi di Torino-Dipartimento di Biotecnologie Molecolari e Scienze della Salute
    Full Title: A MULTICENTER, RANDOMIZED, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCyd) as pre transplant INDUCTION and post transplant consolidation or CARFILZOMIB, LENALIDO...
    Medical condition: NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS TRANSPLANT
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002411-26 Sponsor Protocol Number: UV1/hTERT-2012-P Start Date*: 2013-03-18
    Sponsor Name:Oslo University Hospital
    Full Title: A PHASE I/IIA STUDY OF UV1 VACCINATION IN PATIENTS WITH HORMONE-SENSITIVE METASTATIC PROSTATE CANCER.
    Medical condition: Patients with advanced oligometastatic prostate cancer (PCa) without lung and/or liver metastases who are eligible to Complete Androgen Blockade therapy (GnRH-agonist combined with anti-androgen).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071119 Hormone-dependent prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002987-24 Sponsor Protocol Number: 152CL201 Start Date*: 2007-06-25
    Sponsor Name:Biogen Idec Ltd
    Full Title: A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination with Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclopho...
    Medical condition: Relapsed Chronic Lymphocytic Leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008956 Chronic lymphatic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Prematurely Ended) ES (Completed) IT (Prematurely Ended) FR (Completed) DE (Prematurely Ended) GB (Completed) CZ (Prematurely Ended) SK (Completed) PT (Prematurely Ended) LT (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002204-25 Sponsor Protocol Number: 152CL202 Start Date*: 2009-04-21
    Sponsor Name:Biogen Idec Ltd
    Full Title: A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Combination with Lumiliximab Versus FCR Alone in Subjects with P...
    Medical condition: Previously Untreated Chronic Lymphocytic Leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008958 Chronic lymphocytic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Completed) BE (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021111-17 Sponsor Protocol Number: IST-CAR-506 Start Date*: 2011-05-16
    Sponsor Name:HOVON Foundation
    Full Title: A MULTICENTER, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
    Medical condition: newly diagnosed multiple myeloma patients
    Disease: Version SOC Term Classification Code Term Level
    13.1 10005329 - Blood and lymphatic system disorders 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004928-39 Sponsor Protocol Number: D-FR-01070-002 Start Date*: 2017-11-23
    Sponsor Name:Ipsen Pharma
    Full Title: A multicentre, randomised, dose-confirmation, factorial phase II study to evaluate the optimal dose of 68Ga-OPS202 as a PET imaging agent in subjects with gastroenteropancreatic neuroendocrine tumo...
    Medical condition: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) NL (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003779-20 Sponsor Protocol Number: SCO101-001 Start Date*: 2020-01-28
    Sponsor Name:Scandion Oncology A/S
    Full Title: An open-label phase II prospective clinical trial to investigate safety, tolerability, maximum tolerated dose and anti-tumor effect for SCO-101 in combination with FOLFIRI as a safe and efficient t...
    Medical condition: Metastatic or advanced colorectal cancer (mCRC) with acquired resistance to chemotherapy 
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) DE (Completed) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 23:43:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA